Smith & Nephew sees good quarter with knees, AWM

Knees, sports medicine joint repair, and advanced wound management (AWM) helped boost Smith & Nephew ($SNN) to a good first quarter, as revenues rose 3% to $1.08 billion.

The company saw 6% revenue growth in its knee implant franchise, outperforming the market. CEO Olivier Bohuon said the company saw particular growth in Australia and New Zealand, which had a weak quarter last year after the earthquake. Sports medicine joint repair saw growth of 7%, and AWM grew 5%. However, hips continued to drag, with revenues down 2% on "continued headwinds in the metal-on-metal total hip replacement sector," the company said in a statement.

In a theme echoed throughout the device industry, emerging markets are boosting the company. BRIC countries in particular saw strong revenue growth (20%).

An enthusiastic Bohuon praised his company's performance. "Smith & Nephew has had a good first quarter," he said in a statement. "We grew revenue, increased profit and improved our trading profit margin. We saw the first results of our actions to make Smith & Nephew more fit and effective." Bohuon came on board last year as the company started a restructuring program, which includes a workforce reduction that is ongoing.

Still, with the uncertain economic forecast in the U.S., Savvas Neophytou of Panmure said the future could be interesting for Smith & Nephew. "If the consumer and macro environment in the U.S. do not improve for many years, it is our strong view that it will trigger consolidation and note that Smith & Nephew has not been short of suitors in recent years. The company's products and overall offering are excellent,"  Neophytou said, as quoted by Dow Jones. Last year, Stryker ($SYK) and Biomet were named as potential buyers for the company, but nothing has materialized as of yet.

Meanwhile, at least one other analyst is pretty happy with the U.K.-based company's results. "I'm really quite pleased with the numbers," Cenkos Securities' Navid Malik said in an interview with Bloomberg. "Going into these results, there was a lot of concern about orthopedics. Outside of hips, everything appears to be growing."

- check out the Smith & Nephew statement
- read more from Dow Jones (reg. req.)
- see the Bloomberg story

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.